Oral Versus Nasal Intubation in Infants and Young Children with Heart Disease: A Systematic Review and Meta-analysis.

Pediatr CardiolNov 13, 2025 (epub)
Clinical ResearchPediatricsCardiologyOpen access

Diana L Geisser, Joshua Feder, Chloe Rotman et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis compared oral with nasal intubation in children with cardiac disease, focusing pooled analyses on patients aged ≤2 years. Fifteen studies were identified, including two randomised trials; 13 contributed to meta-analysis. Compared with nasal intubation, oral intubation was associated with higher pooled odds of severe adverse events (OR 2.82, 95% CI 1.24-6.40), multiple attempts and unplanned extubation, but lower odds of inability to intubate (OR 0.06, 95% CI 0.01-0.46). The authors considered nasal intubation a reasonable option where teams have relevant expertise.

Key findings

  • Oral intubation was associated with greater odds of severe adverse events than nasal intubation: OR 2.82 (95%CI 1.24-6.40).
  • Oral intubation was associated with greater odds of multiple intubation attempts [1.49 (95% CI:1.06-2.10)] and unplanned extubation [OR 1.63 (95% CI 1.27-2.09)].
  • Oral intubation was associated with lower odds of being unable to intubate: OR 0.06 (95% CI 0.01-0.46).
  • Oral intubation was associated with 37% greater median time to full oral feeds [OR 1.37 (95%CI 1.15-1.64)].

Why it matters

Intubation route may be associated with differences in airway safety, tube security and feeding outcomes in young children with cardiac disease. These pooled findings can inform discussion of route selection, while the lower odds of inability to intubate with the oral route underscore that outcomes do not uniformly favour nasal intubation.

What to keep in mind

The evidence included varied study designs, with only two randomised trials and four studies judged at low risk of bias. The pooled findings are associations and may be affected by differences between studies.

Source

Published in Pediatr Cardiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.